Youngil Koh, CEO, is the founder and oversees research and development essential for new drug development.
He is also a professor in the Hematology-Oncology Department at Seoul National University Hospital and actively engages in collaborative research with various researchers and companies.
EDUCATION
- PhD., Molecular and Clinical Oncology, Seoul National University, Korea
- Medical Doctor, Seoul National University College of Medicine, Korea
KEY PUBLICATION
- 30+ publications (Blood Cancer Journal, Hematologica, Nature Communications, etc.)
CLINICAL TRIAL EXPERIENCE
Conducted 40+ clinical trials
- An open–label, multicenter, phase1 trial valuating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma
- A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
- A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies
- A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)
